Jason Adelstone is a seasoned business lawyer, international policy advisor, and problem solver. Based in Denver, Colorado, he provides domestic and international legal counsel to a diverse clientele, including entrepreneurs, corporations, religious organizations, and federal and international cannabis operators. His practice spans corporate law, international policy, and cannabis regulatory compliance, helping clients navigate the complexities of the global cannabis industry and beyond.
On Friday, October 30, the Justice Department announced the issuance of federal registrations for medical marijuana dispensaries. Simultaneously, DEA released its Timely Applicant information, outlining operational requirements for applicants that sought registration during the expedited application window between April 28 and June 26, 2026. The Timely Applicant information defines a “Timely Applicant” as a state
We recently hosted a webinar titled “DEA Enforcement in a Changing Cannabis Landscape, Rescheduling Hemp, and What Comes Next”. We had just one hour to cover topics that could easily fill several hours of discussion. Unsurprisingly, the chat was buzzing with questions, and we were unable to get to all of them. This post addresses
Recently on the podcast High Spirits: The Cannabis Business Podcast, I discussed how cannabis legalization can occur through executive action, not just congressional action. This post will expand on what we discussed on the podcast. My co-founder, Amna Shamim, and I started Project Four 2029 to engage with presidential and congressional candidates ahead of the
What just happened in the marijuana rescheduling hearing On September 28, 2026, three participants in the ALJ marijuana rescheduling hearing filed a “Joint Motion for Leave to File Supplemental Briefing, for Admission of Supplemental Exhibit, and for Stay of Proceedings.” The motion was submitted by DUID Victim Voices, Kenneth Finn, M.D., and the National Drug
On September 9th, the United States Court of Appeals for the District of Columbia denied a motion to stay filed by SAM, Inc. and the National Drug and Alcohol Screening Association, Inc. (collectively, “SAM”). The motion sought to stay (pause) the Attorney General’s final order placing state legal medical marijuana into Schedule III of the
Colorado regulates marijuana businesses through the state Marijuana Enforcement Division (MED), while local jurisdictions retain separate licensing and regulatory authority over marijuana businesses within their boundaries. The current Colorado Marijuana Rules are codified at 1 CCR 212-3 (version effective January 5, 2026). Because state rules, forms, fee schedules, and local ordinances can change, applicants should
With so much of my attention focused on U.S. rescheduling lately, I wanted to take advantage of the D.C. Circuit’s delay and the DEA ALJ’s delayed timeline. This gives me an opportunity to get back into some considerations on international cannabis reform. Who controls government is one of the most important factors when discussing cannabis
Cannabis law has never been more contradictory. In the U.S., federal and state governments often regulate identical products under completely different legal frameworks. Hemp and marijuana can produce the same intoxicating effects, yet lawmakers treat them as fundamentally different. Medical marijuana now occupies a unique place under federal law while adult use marijuana remains prohibited.
While most attention has focused on the recently concluded marijuana rescheduling hearing, an equally significant legal battle has unfolded in the D.C. Circuit over the final rescheduling order ("Final Order"). Petitioners, the Department of Justice, newly intervening parties, and amici participants have exchanged a series of briefs over the past month. Those filings may ultimately
When I first met Martin Jelsma (retiring as Programme Director Drugs & Democracy at the Transnational Institute) in 2019, I was a law clerk who, from day one, began following developments in international cannabis policy. At the time, I was trying to understand the intricate architecture of the international drug control treaties—how they functioned, how
